Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908948 | 0.90 | USP2 (0.40) | HSD11B1USP2SMN1; SMN2CTSKHPGD | |
| SCHEMBL4629128 | 0.74 | USP2 (0.41) | HSD11B1USP2SMN1; SMN2CTSKHPGD | |
| SCHEMBL3586646 | 0.72 | PER2 (0.37) | PER2CRY1CRY2 | |
| SCHEMBL16617849 | 0.70 | USP2 (0.45) | HSD11B1USP2SMN1; SMN2CTSKHPGD | |
| SCHEMBL22148462 | 0.69 | PER2 (0.35) | PER2CRY1CRY2 | |
| SCHEMBL4066309 | 0.69 | USP2 (0.37) | HSD11B1USP2SMN1; SMN2CTSKHPGD | |
| SCHEMBL6350119 | 0.68 | USP2 (0.55) | USP2SMN1; SMN2CTSKHPGDEPHX1 | |
| SCHEMBL2125387 | 0.68 | USP2 (0.42) | USP2SMN1; SMN2CTSKHPGDEPHX1 | |
| SCHEMBL22574311 | 0.67 | USP2 (0.41) | HSD11B1USP2SMN1; SMN2CTSKHPGD | |
| SCHEMBL14653322 | 0.67 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740723-B1 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2017-05-10 | — | — | EP | disclosed |
| US-9073906-B2 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-07-07 | — | — | US | disclosed |
| US-9073906-B2 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-07-07 | — | — | US | disclosed |
| EP-2740723-A2 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Korea Research Institute of Chemical Technology (KR) | 2014-06-11 | — | — | EP | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| EP-1879885-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20060252785-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-11-09 | — | — | US | disclosed |
| WO-2006117306-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252785-A1 | Heterocyclic antiviral compounds | EIF2AK2, HAVCR2, POLR2E | HSD11B1 1990/4885USP2 3214/4885SMN1; SMN2 3231/4885 |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885USP2 1687/4885SMN1; SMN2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.